What can be scary than receiving a medical report of been infected with an incurable viral disease like HIV after going through a test? These deadly viruses are present all over the world freely spreading like wildfire. Every human being on the surface of the earth is highly vulnerable to the onslaught of these dreadful viruses. Quite a great number of individuals are dead as a result of them while several are struggling to regain their health in medical centers. It is wisdom to take seriously various protective measures so as to be secured from these pandemic viruses. It is advisable to maintain proper hygiene and isolate oneself from infected individuals or be careful on your interactions with them.
There are several medical therapy treatments already propounded to treat and prevent several viral infections. Among them are retroviral drugs created to limit the effect of HIV virus in infected persons. Acyclovir was majorly fabricated to treat cold sores, herpes simplex Infections, and varicella-zoster. Copegus which is our main focus here is one potent antiviral made to treat and mitigate the effect of hepatitis C virus on the host. Copegus acts by terminating the formation of the RNA chain thereby inhibiting the replication of the virus in the body. Copegus will be effective when combined with another highly effective antiviral vaccine to treat Hepatitis C.
Discovery and Approval of Copegus Therapy Treatment for Hepatitis C
As mentioned earlier, Copegus will not be effective when administered alone. It can only be effective when administered in conjunction with another potent antiviral vaccine to treat hepatitis C. About four years ago, the U.S Food and Drug Administration approved the use of Copegus with another highly effective antiviral drug known as Roche’s Pegasys for hepatitis C treatment. About 8 million individuals in the United States and Europe are ravaged by hepatitis C virus. Many individuals are suffering from hepatitis infection around the world. As a result of the method discovered to combine two antiviral vaccines, a decline as occurred in the number of infected persons which indicates that the virus can be eradicated if properly managed. Copegus is a trade name of ribavirin drug, a known antiviral vaccine for treating hepatitis C.
Causes of Hepatitis C
Hepatitis C is a contagious disease that affects the liver and it is solely caused by a virus. It is known to be very common in the United States and Europe. Millions of individuals are suffering from its terror and sometimes may not be noticeable to the carrier. It is majorly transferred through blood contact and It is so serious a health challenge that no known immunization is available for it. In other words, every human being is prone to contracting hepatitis C. The only way of prevention is to protect yourself from being exposed to infected individuals.
The infection can become chronic after 6months if not treated on time by using drug therapy treatment like a combination of Copegus and Pegasys. Untreated infection often results in cancer of the liver, cirrhosis or even death. Hepatitis C is often known as the silent pandemic disease as it can go unnoticed without been detected. The infection is caused by an RNA virus which replicates rapidly in the body if not dealt with immediately. Copegus interrupts the RNA chain formation to hinder the virus from replicating.
Success Stories on the usage of Copegus
The success stories on the usage of ribavirin drug are published to encourage individuals and prove the potency of antiviral vaccines available to treat hepatitis C. They are experiences collected and shared online by those directly concerned. Someone testified that he used an intravenous drug for 18 years and that he knew he had hepatitis C. After discovering his genotype 6years ago, he got his first round of treatment by using ribavirin and Pegasys. After series of failure, he tried ribavirin, Pegasys, and Sovaldi. He got his 12 weeks’ post treatment result and was diagnosed hepatitis C free. Another individual stated that she lost her boyfriend to hepatitis C and was eventually diagnosed with the same disease. Sovaldi and ribavirin regimen was administered to her for 6months. She made mention that she was genotype 3a and her cure rate was 87%. She took her last treatment in 2014 and was declared hepatitis C free after her first lab follows up and viral count in January 2015.